CAT and chronic kidney disease: The final CKD stage during the observation period was 12.9% and 14.1% (P = 0.65) in renal replacement therapy (G5D); 4.2% and 5.7% (P = 0.37) in G5; 10.2% and 11.4% (P = 0.62) in G4; 16.5% and 12.3% in G3b; and 40.8% and 39.3% (P = 0.69) in G3a in the CAT and non-CAT groups, respectively.